Quality of life in patients with aggressive non-Hodgkin's lymphoma. Validation of the medical outcomes study short form 20 and the Rotterdam symptom checklist in older patients

• Published in: Critical reviews in oncology/hematology Vol. 43; no. 3; pp. 219 - 226
• Main Authors: Tchen, Nadine, Soubeyran, Pierre, Eghbali, Houchingue, Ceccaldi, Joël, Cany, Laurent, Balzon, Jean-Claude, Remuzon, Philippe, Malet, Maxime, Bonichon, Françoise, Picot, Véronique, Monnereau, Alain, Hœrni, Bernard
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier Ireland Ltd 01-09-2002; Elsevier Science
• Subjects: Aged; Aged, 80 and over; Aggressive lymphoma; Algorithms; Analysis of Variance; Biological and medical sciences; Elderly; Geriatric Assessment - methods; Hematologic and hematopoietic diseases; Humans; Language; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphoma, Non-Hodgkin - diagnosis; Medical sciences; MOS SF20; Quality of Life; RSCL; Severity of Illness Index; Surveys and Questionnaires - standards; Treatment Outcome; Validation; Validation; IQOLA, international quality of life assessment; QoL, quality of life; Aggressive lymphoma; RSCL; MOS SF20, Medical Outcomes Study Short Form 20; PS, performance status; Quality of life; QLQ-C30, EORTC quality of life questionnaire—30 questions; MOS SF20; NHL, non-Hodgkin's lymphoma; RSCL, Rotterdam symptom checklist; Elderly; MOS SF36, Medical Outcomes Study Short Form 36; Human; Validity; Questionnaire; Lymphoproliferative syndrome; Evolution; Malignant hemopathy; Non Hodgkin lymphoma; Measurement scale
• ISSN: 1040-8428; 1879-0461
• DOI: 10.1016/S1040-8428(01)00200-1

In the elderly population, cancer treatment aims to cure and/or maintain Quality of Life (QoL). However, there is little QoL data to provide evidence for QoL benefits for some of the cancer treatments. This pilot study developed valid QoL questionnaires in French, for patients over 65 years with a diagnosis of large cell lymphoma, part of the Lymâge phase II study. They were asked to complete two questionnaires, the Medical Outcomes Study Short Form 20 (MOS SF20; generic) and the Rotterdam symptom checklist (RSCL; cancer-specific). Between June 1995 and April 1997, questionnaires were returned by 63 of 89 patients. This article reports the process undertaken to adapt the English version to a French setting, and provides the results of factor analysis, convergent and discriminant validity and reliability. Our data suggest that QoL questionnaires can be used in elderly patients. These two questionnaires are validated in French and would help us to analyse the QoL of elderly patients with the development of new treatments as done in the Lymâge study.